{"id":311587,"date":"2026-02-26T17:14:07","date_gmt":"2026-02-26T17:14:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/311587\/"},"modified":"2026-02-26T17:14:07","modified_gmt":"2026-02-26T17:14:07","slug":"new-long-term-analysis-suggests-follicular-lymphoma-can-be-cured","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/311587\/","title":{"rendered":"New long-term analysis suggests follicular lymphoma can be cured"},"content":{"rendered":"<p>These findings could have long-reaching effects on patient care for people diagnosed with follicular lymphoma, Shadman said.<\/p>\n<p>\u201cWe always start by saying \u2018You start with me this year, you\u2019ll stay with me for the rest of your life. We can treat your disease, but we&#8217;ll never discharge you from the cancer center,\u2019\u201d he said. In contrast, some patients with other types of lymphomas (such as aggressive lymphomas) that are considered curable may eventually \u201cgraduate\u201d back into a standard care environment.<\/p>\n<p>\u201cNow, we can just give the hope [to patients with follicular lymphoma] that yes, you may be someone who, after a few years, we can send back to your primary care provider,\u201d Shadman said. \u201cThese findings also support eliminating the need for indefinite radiologic surveillance.\u201d<\/p>\n<p>The analysis also highlights how well R-CHOP (CHOP plus rituximab) can work, despite being a treatment regimen of long-standing. Oncologists could have a higher-level discussion with their patients, who Shadman said should not dismiss chemotherapy just because it\u2019s chemotherapy and not the newest treatment available.<\/p>\n<p>And if chemoimmunotherapy can cure some patients, the bar for new treatments has been set higher as well, Shadman noted. The analysis suggests that lower-risk FL patients were more likely to end up in that 42%, so it may also be that trials of new therapies should focus on patients with higher-risk FL who are less likely to be cured with standard treatment.<\/p>\n<p>Shadman noted that the new work also highlights the importance of clinical trial participation. In addition to revealing the efficacy of a treatment, clinical trials also reveal potential long-term toxicities and side effects, such as risk of secondary malignancies.<\/p>\n<p>\u201cThere is no way you can have a high-quality 15-year follow-up if patients are not in a clinical trial,\u201d Shadman said.<\/p>\n<p>The current analysis is the latest of multiple\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23233710\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">scientific<\/a> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29356608\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">papers<\/a> to <a href=\"https:\/\/www.fredhutch.org\/en\/news\/center-news\/2006\/10\/longer-life.html\" rel=\"nofollow noopener\" target=\"_blank\">come out of the trial<\/a>, initiated by Press, who mentored Shadman. Press was renowned for <a href=\"https:\/\/www.fredhutch.org\/en\/news\/center-news\/2017\/05\/cancer-doctor-oliver-press-impact.html\" rel=\"nofollow noopener\" target=\"_blank\">his mentorship, patient care and scientific vision<\/a>.<\/p>\n<p>He pioneered the development and use of radio-labeled antibodies, which help focus cancer-killing radiation in tumors, for lymphoma treatment. More than a decade later, the trial Press conducted is still providing insights that could improve patient care and future lymphoma research.<\/p>\n<p>\u201cIt\u2019s a wonderful testament to Ollie and his vision,\u201d Shadman said.<\/p>\n","protected":false},"excerpt":{"rendered":"These findings could have long-reaching effects on patient care for people diagnosed with follicular lymphoma, Shadman said. \u201cWe&hellip;\n","protected":false},"author":2,"featured_media":311588,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[6136,1309,7993,97685,163,85,46,156106,156104,156103,156102,156105],"class_list":{"0":"post-311587","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-biostatistics","9":"tag-chemotherapy","10":"tag-clinical-trial","11":"tag-follicular-lymphoma","12":"tag-health","13":"tag-il","14":"tag-israel","15":"tag-long-term-follow-up","16":"tag-mathematical-modeling","17":"tag-mazyar-shadman","18":"tag-michael-leblanc","19":"tag-oliver-press"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/311587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=311587"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/311587\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/311588"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=311587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=311587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=311587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}